PL2544682T3 - Fitokannabinoidy w leczeniu glejaka - Google Patents
Fitokannabinoidy w leczeniu glejakaInfo
- Publication number
- PL2544682T3 PL2544682T3 PL11709175T PL11709175T PL2544682T3 PL 2544682 T3 PL2544682 T3 PL 2544682T3 PL 11709175 T PL11709175 T PL 11709175T PL 11709175 T PL11709175 T PL 11709175T PL 2544682 T3 PL2544682 T3 PL 2544682T3
- Authority
- PL
- Poland
- Prior art keywords
- phytocannabinoids
- glioblastoma
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1004137.4A GB2478595B (en) | 2010-03-12 | 2010-03-12 | Phytocannabinoids in the treatment of glioma |
| PCT/GB2011/050487 WO2011110866A1 (en) | 2010-03-12 | 2011-03-11 | Phytocannabinoids in the treatment of cancer |
| EP11709175.1A EP2544682B1 (en) | 2010-03-12 | 2011-03-11 | Phytocannabinoids in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2544682T3 true PL2544682T3 (pl) | 2016-08-31 |
Family
ID=42261478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11709175T PL2544682T3 (pl) | 2010-03-12 | 2011-03-11 | Fitokannabinoidy w leczeniu glejaka |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8790719B2 (pl) |
| EP (1) | EP2544682B1 (pl) |
| JP (1) | JP5785569B2 (pl) |
| KR (1) | KR20130067248A (pl) |
| CN (1) | CN102869356A (pl) |
| AR (1) | AR080454A1 (pl) |
| AU (3) | AU2011225837A1 (pl) |
| BR (1) | BR112012023017A8 (pl) |
| CA (1) | CA2792722A1 (pl) |
| CO (1) | CO6630103A2 (pl) |
| CY (1) | CY1117451T1 (pl) |
| DK (1) | DK2544682T3 (pl) |
| EA (1) | EA201290901A1 (pl) |
| ES (1) | ES2569669T3 (pl) |
| GB (1) | GB2478595B (pl) |
| HR (1) | HRP20160427T1 (pl) |
| HU (1) | HUE029817T2 (pl) |
| IL (1) | IL221871A (pl) |
| MX (1) | MX2012010512A (pl) |
| NZ (2) | NZ629136A (pl) |
| PH (1) | PH12012501782A1 (pl) |
| PL (1) | PL2544682T3 (pl) |
| SG (1) | SG184016A1 (pl) |
| SI (1) | SI2544682T1 (pl) |
| TW (1) | TWI461205B (pl) |
| UA (1) | UA109271C2 (pl) |
| WO (1) | WO2011110866A1 (pl) |
| ZA (1) | ZA201207574B (pl) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2377218A (en) * | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
| KR20070089151A (ko) | 2004-11-16 | 2007-08-30 | 지더블유 파마 리미티드 | 카나비노이드의 새로운 용도 |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| GB2460672B (en) * | 2008-06-04 | 2012-01-04 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2494461A (en) * | 2011-09-12 | 2013-03-13 | Gw Pharma Ltd | Phytocannabinoids for use in the treatment of invasive cancers or metastases |
| GB2514054A (en) * | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB201117956D0 (en) * | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
| US9776014B2 (en) | 2012-05-03 | 2017-10-03 | Magdent Ltd. | Bone enhancement device and method |
| CA2895805A1 (en) * | 2012-12-18 | 2014-06-26 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
| CA3012383C (en) | 2013-02-28 | 2021-03-02 | Teewinot Technologies Limited | Biosynthesis of cannabinoids |
| EP2968259B1 (en) | 2013-03-14 | 2022-09-14 | SC Laboratories Inc. | Bioactive concentrates and uses thereof |
| US9095554B2 (en) | 2013-03-15 | 2015-08-04 | Biotech Institute LLC | Breeding, production, processing and use of specialty cannabis |
| US10441617B2 (en) | 2013-03-15 | 2019-10-15 | Biotech Institute, Llc | Breeding, production, processing and use of medical cannabis |
| GB2513167B (en) * | 2013-04-18 | 2016-03-02 | Otsuka Pharma Co Ltd | Tetrahydrocannabivarin for use in the treatment of nausea and vomiting |
| GB2515312A (en) * | 2013-06-19 | 2014-12-24 | Gw Pharma Ltd | The use of phytocannabinoids in the treatment of ovarian carcinoma |
| GB2516814B (en) * | 2013-06-19 | 2016-08-31 | Otsuka Pharma Co Ltd | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
| US10774288B2 (en) * | 2013-09-18 | 2020-09-15 | The Werc Shop, LLC | Terpene-based compositions, processes, methodologies for creation and products thereby |
| AU2014347807A1 (en) * | 2013-10-31 | 2016-05-26 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2527590A (en) * | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| AU2015292915B2 (en) | 2014-07-21 | 2020-10-15 | Pharmaceutical Productions, Inc. | Solid dosage form composition for buccal or sublingual administration of cannabinoids |
| JP6622793B2 (ja) | 2014-08-25 | 2019-12-18 | ティーウィノット テクノロジーズ リミテッド | カンナビノイド化合物を同時作製する装置及び方法 |
| CA2961410C (en) | 2014-09-16 | 2023-07-11 | India Globalization Capital, Inc. | Cannabinoid composition and method for treating pain |
| WO2016054268A1 (en) | 2014-09-30 | 2016-04-07 | MJAR Holdings, LLC | Methods of growing cannabaceae plants using artificial lighting |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| CN107205960A (zh) * | 2014-10-21 | 2017-09-26 | 联合大麻公司 | 大麻提取物及其制备和使用方法 |
| CN104277917B (zh) * | 2014-10-24 | 2018-02-09 | 汉康(云南)生物科技有限公司 | 一种富含大麻二酚的工业大麻精油提取方法及其提取设备 |
| WO2016105514A1 (en) | 2014-12-23 | 2016-06-30 | Biotech Institute, Llc | A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis |
| CA2974895A1 (en) | 2015-01-25 | 2016-07-28 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
| CA3012599A1 (en) | 2015-01-26 | 2016-08-04 | Matthew W. Giese | Systems, apparatuses, and methods for classification |
| CA2974292C (en) | 2015-01-31 | 2024-04-16 | Constance Therapeutics, Inc. | Methods for preparation of cannabis oil extracts and compositions |
| US10238745B2 (en) | 2015-01-31 | 2019-03-26 | Constance Therapeutics, Inc. | Cannabinoid composition and products including α-tocopherol |
| AU2016225026A1 (en) * | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| CN107405314A (zh) * | 2015-02-27 | 2017-11-28 | 埃布公司 | 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物 |
| US12303541B2 (en) | 2015-04-01 | 2025-05-20 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Erodium crassifolium L'Her plant extracts and uses thereof |
| EP3277260B1 (en) | 2015-04-01 | 2021-05-12 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Erodium crassifolium l'her plant extracts and uses thereof |
| CA2985065A1 (en) * | 2015-05-07 | 2016-11-10 | Mark Andrew Scialdone | Hydrogenation of cannabis oil |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| EP3319446A4 (en) * | 2015-07-06 | 2019-07-03 | Cg- Bio Genomics, Inc. | Healthful supplements |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10596159B2 (en) | 2015-08-12 | 2020-03-24 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
| WO2017091764A1 (en) * | 2015-11-24 | 2017-06-01 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
| MX421795B (es) * | 2016-03-18 | 2025-03-14 | Christopher Brian Reid | Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| CA3027862A1 (en) | 2016-06-15 | 2017-12-21 | India Globalization Capital, Inc. | Method and composition for treating seizure disorders |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| KR20190034576A (ko) * | 2016-08-03 | 2019-04-02 | 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 | 카나비스 조성물 |
| BR112019001852A2 (pt) * | 2016-08-03 | 2019-05-07 | Zelda Therapeutics Operations Pty Ltd | composição de cannabis |
| SG11201900596XA (en) * | 2016-08-03 | 2019-02-27 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| US10568865B2 (en) | 2016-08-29 | 2020-02-25 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
| US12485129B2 (en) | 2016-08-29 | 2025-12-02 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| WO2018160827A1 (en) * | 2017-03-01 | 2018-09-07 | Ebbu, LLC | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
| EP3592346A4 (en) * | 2017-03-05 | 2020-12-30 | The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| WO2018205038A1 (en) * | 2017-05-12 | 2018-11-15 | Tetra Bio-Pharma Inc. | Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling |
| WO2018217803A2 (en) * | 2017-05-22 | 2018-11-29 | Growblox Life Sciences L.L.C. | Myrcene-containing complex mixtures targeting trpv1 |
| KR20200104278A (ko) | 2017-06-19 | 2020-09-03 | 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 | 수면 장애 조성물 및 그의 치료 |
| JP2020524679A (ja) | 2017-06-20 | 2020-08-20 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | カンナビジオール酸エステル組成物およびその使用 |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| EP3644976A4 (en) * | 2017-06-28 | 2021-03-24 | Buzzelet Development And Technologies Ltd | TERPEN-ENRICHED CANNABINOID PRODUCT FOR WOMEN'S HEALTH |
| CA3079537A1 (en) * | 2017-09-02 | 2019-03-07 | Scientific Holdings, Llc | Tetrahydrocannabinol modulators |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| CN108204786A (zh) * | 2018-01-15 | 2018-06-26 | 武汉盛硕电子有限公司 | 一种基于手机模块的北斗测量系统 |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| AU2019210332A1 (en) * | 2018-01-22 | 2020-09-10 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
| WO2019157195A1 (en) | 2018-02-08 | 2019-08-15 | Neonc Technologies, Inc | Methods of permeabilizing the blood brain barrier |
| KR102041875B1 (ko) | 2018-02-14 | 2019-11-08 | (주)카이언바이오텍 | 대마로부터 추출된 칸나비디올 추출물 및 트레일을 함유하는 대장암 예방 또는 치료용 약학 조성물 |
| KR20190098649A (ko) | 2018-02-14 | 2019-08-22 | (주)카이언바이오텍 | 칸나비디올 추출물을 함유하는 대장암 예방 또는 치료용 약학 조성물 |
| EP3755318B1 (en) * | 2018-02-20 | 2022-08-24 | MyMD Pharmaceuticals, Inc. | Genetically modified cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders |
| CA3095729A1 (en) | 2018-03-30 | 2019-10-03 | India Globalization Capital, Inc. | Method and composition for treating cns disorders |
| EP3773722A1 (en) | 2018-04-04 | 2021-02-17 | Jay Pharma Inc. | Combination of a cannabinoid and a chemotheraopeutic agent for the treatment of breast cancer |
| MX2020010603A (es) | 2018-04-09 | 2021-02-02 | Ellevet Sciences | Extracto de cáñamo para tratamiento de dolor en animales. |
| WO2019227167A1 (en) * | 2018-06-01 | 2019-12-05 | The University Of Sydney | Compositions and treatments |
| WO2020012315A1 (en) | 2018-07-08 | 2020-01-16 | Buzzelet Development And Technologies Ltd. | Terpene-enriched cannabinoid composition for treatment of male subjects |
| EP3666765A1 (en) * | 2018-12-11 | 2020-06-17 | Emerald Health Biotechnology España,S.L.U. | Chromenic phytocannabinoids, their synthesis and use in treatment or prevention of disease |
| CA3123773A1 (en) * | 2018-12-12 | 2020-06-18 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl) |
| CA3128054A1 (en) * | 2019-01-31 | 2020-08-06 | Cava Healthcare Inc. | Compounds for increasing mhc-i expression and modulating histone deacetylase activity |
| NL2022614B1 (en) * | 2019-02-21 | 2020-08-31 | Patrick Alexander Unger | Pharmaceutical, phyto-cannabinoid based compositions |
| MX2021010875A (es) | 2019-03-12 | 2021-12-10 | Epm Ip Inc | Composiciones de éster de ácido cannabinoide y sus usos. |
| EP3946307A4 (en) * | 2019-04-02 | 2022-12-14 | Ulagaraj Selvaraj | SOLID NANOPARTICLE FORMULATION OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD RIPENING AND IMMEDIATE DRUG RELEASE AFTER INTRAVENOUS ADMINISTRATION |
| ES2986503T3 (es) | 2019-05-03 | 2024-11-11 | Zyus Life Sciences Inc | Formulación para el manejo del dolor que comprende tetrahidrocannabinol (THC), cannabicromeno (CBC) y cannabidiol (CBD) en una proporción determinada |
| US12178797B2 (en) | 2019-05-03 | 2024-12-31 | Zyus Life Sciences Inc. | Formulation for pain management |
| US12220396B2 (en) | 2019-05-03 | 2025-02-11 | Zyus Life Sciences Inc. | Formulation for pain management |
| CA3140290A1 (en) * | 2019-05-16 | 2020-11-19 | Technion Research & Development Foundation Limited | Cannabinoids and uses thereof |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| CN111184710A (zh) * | 2020-03-02 | 2020-05-22 | 福建省中科生物股份有限公司 | 一种环酚的应用和制备方法 |
| CA3175684A1 (en) | 2020-04-29 | 2021-11-04 | Jon Penarando Saez | Cannabinoids for use in supressing cancer stem cells |
| EP3912485A1 (en) | 2020-05-18 | 2021-11-24 | Del-Vis Sp. z o.o. | Cigarette product and a method for manufacturing the product |
| CN111773390B (zh) * | 2020-07-01 | 2021-08-20 | 南京大学 | 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用 |
| JP2023534073A (ja) * | 2020-07-22 | 2023-08-07 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 銀強化カンナビノイド抗生物質 |
| EP4203925A1 (en) * | 2020-08-31 | 2023-07-05 | Nelson Mandela University | Cannabinoid combinations and their use in the treatment of cancer |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US20240041902A1 (en) * | 2020-12-08 | 2024-02-08 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization | Compositions and methods for the treatment of urothelial cancer |
| WO2022215071A1 (en) * | 2021-04-05 | 2022-10-13 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) | Compositions and methods for the treatment of cancer |
| WO2022232574A1 (en) | 2021-04-29 | 2022-11-03 | Tilray, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| EP4422769A2 (en) | 2021-10-26 | 2024-09-04 | Ecofibre USA Inc. | Systems and methods for producing hemp extracts and compositions |
| WO2023076937A1 (en) | 2021-10-26 | 2023-05-04 | Ecofibre Limited | Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract |
| JP2024540177A (ja) | 2021-10-26 | 2024-10-31 | エコファイバー ユーエスエイ インコーポレイテッド | ヘンプ抽出物を使用する子宮内膜がんを処置する方法 |
| WO2023130161A1 (en) * | 2022-01-10 | 2023-07-13 | Dolce Cann Global Pty Ltd | Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda) along with an additional active agent |
| WO2023130160A1 (en) * | 2022-01-10 | 2023-07-13 | Dolce Cann Global Pty Ltd | Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda). |
| US12440454B2 (en) | 2022-02-01 | 2025-10-14 | Portland Technology Holdings Llc | Pharmaceutical compositions containing hemp extract for administration to felines and related methods |
| WO2023161921A2 (en) * | 2022-02-23 | 2023-08-31 | Cannabotech Ltd. | Compositions for use as an adjunctive therapy in the treatment of breast cancer |
| WO2023239415A1 (en) * | 2022-06-08 | 2023-12-14 | Angrow Company Limited | Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject |
| WO2023238114A1 (en) * | 2022-06-08 | 2023-12-14 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) | Combinations and methods for the treatment of cancer |
| WO2024082014A1 (en) * | 2022-10-21 | 2024-04-25 | Dolce Cann Global Pty Ltd | Compositions comprising cannabidiolic acid and fatty acids |
| EP4608426A1 (en) | 2022-10-26 | 2025-09-03 | Ecofibre USA Inc. | Stabilized compositions comprising cannabidiol |
| US12097211B2 (en) | 2022-10-26 | 2024-09-24 | Ecofibre USA Inc. | Methods of treating estrogen sensitive diseases with cannabis extract |
| CN115583933B (zh) * | 2022-10-31 | 2024-02-06 | 暨明医药科技（苏州）有限公司 | 一种高纯度四氢大麻素同系物的制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2238707A (en) | 1989-12-08 | 1991-06-12 | Peter Bullock | Repairing footwear |
| US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| US20040039048A1 (en) | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
| ES1045342Y (es) | 2000-02-11 | 2001-02-16 | Alvarez Manuel Couto | Expositor giratorio para postales, fotos y similares. |
| ES2164584A1 (es) | 2000-02-11 | 2002-02-16 | Univ Madrid Complutense | Terapia con cannabinoides para el tratamiento de tumores cerebrales. |
| US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| EP1326996A4 (en) | 2000-09-14 | 2005-08-24 | Univ California | ID-1 AND ID-2 GENES AND PRODUCTS AS DIAGNOSTIC OR PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR THE TREATMENT OF BREAST CANCER AND OTHER TYPES OF CARCINOMA |
| DE10051427C1 (de) * | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
| US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
| GB2380129B (en) | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
| CH695661A5 (de) | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
| GB0202385D0 (en) * | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
| WO2003063847A1 (en) | 2002-02-01 | 2003-08-07 | Gw Pharma Limited | Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
| US20080057117A1 (en) | 2002-02-15 | 2008-03-06 | Forschungs Institut Miscia Verenfur Krebsforschung | Pharmaceutical composition made up of cannibus extracts |
| IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
| US7285687B2 (en) | 2002-04-25 | 2007-10-23 | Virginia Commonwealth University | Cannabinoids |
| GB2391865B (en) | 2002-08-14 | 2005-06-01 | Gw Pharma Ltd | Improvements in the extraction of pharmaceutically active components from plant materials |
| US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
| GB2394894B (en) | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
| GB2414933B (en) | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| GB2418612A (en) * | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
| KR101288729B1 (ko) | 2005-04-01 | 2013-07-23 | 인터자인 테크놀로지스, 인코포레이티드 | 약물 전달용 중합체성 마이셀 |
| US7968594B2 (en) | 2005-04-27 | 2011-06-28 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of pain |
| EP1881757A4 (en) | 2005-05-13 | 2008-09-10 | Unimed Pharmaceuticals Inc | DRONABINOL TREATMENT OF CHEMOTHERAPY-INDUCED POSSIBLE INCOMPATIBILITY AND ILLUSTRATION |
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| US20080103193A1 (en) * | 2006-10-26 | 2008-05-01 | Trevor Percival Castor | Methods for making compositions and compositions for treating pain and cachexia |
| US20100152238A1 (en) * | 2007-03-05 | 2010-06-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies |
| GB2448535A (en) * | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
| WO2008144475A1 (en) | 2007-05-17 | 2008-11-27 | California Pacific Medical Center | Methods and compositions for treating cancer |
| GB2449691A (en) * | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
| GB2450741A (en) * | 2007-07-05 | 2009-01-07 | Gw Pharma Ltd | Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease |
| ES2359168T3 (es) * | 2007-10-02 | 2011-05-19 | Vivacell Biotechnology España S.L. | Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias. |
| GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2460672B (en) * | 2008-06-04 | 2012-01-04 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
-
2010
- 2010-03-12 GB GB1004137.4A patent/GB2478595B/en active Active
-
2011
- 2011-03-03 AR ARP110100670A patent/AR080454A1/es unknown
- 2011-03-09 TW TW100107897A patent/TWI461205B/zh not_active IP Right Cessation
- 2011-03-11 MX MX2012010512A patent/MX2012010512A/es not_active Application Discontinuation
- 2011-03-11 BR BR112012023017A patent/BR112012023017A8/pt not_active IP Right Cessation
- 2011-03-11 PL PL11709175T patent/PL2544682T3/pl unknown
- 2011-03-11 AU AU2011225837A patent/AU2011225837A1/en not_active Abandoned
- 2011-03-11 US US13/634,343 patent/US8790719B2/en active Active
- 2011-03-11 HR HRP20160427TT patent/HRP20160427T1/hr unknown
- 2011-03-11 UA UAA201211775A patent/UA109271C2/uk unknown
- 2011-03-11 CA CA2792722A patent/CA2792722A1/en not_active Abandoned
- 2011-03-11 KR KR1020127026659A patent/KR20130067248A/ko not_active Ceased
- 2011-03-11 HU HUE11709175A patent/HUE029817T2/en unknown
- 2011-03-11 EP EP11709175.1A patent/EP2544682B1/en active Active
- 2011-03-11 SG SG2012067393A patent/SG184016A1/en unknown
- 2011-03-11 NZ NZ629136A patent/NZ629136A/en unknown
- 2011-03-11 SI SI201130799A patent/SI2544682T1/sl unknown
- 2011-03-11 NZ NZ602953A patent/NZ602953A/en unknown
- 2011-03-11 DK DK11709175.1T patent/DK2544682T3/en active
- 2011-03-11 CN CN2011800236521A patent/CN102869356A/zh active Pending
- 2011-03-11 JP JP2012556592A patent/JP5785569B2/ja active Active
- 2011-03-11 PH PH1/2012/501782A patent/PH12012501782A1/en unknown
- 2011-03-11 WO PCT/GB2011/050487 patent/WO2011110866A1/en not_active Ceased
- 2011-03-11 ES ES11709175.1T patent/ES2569669T3/es active Active
- 2011-03-11 EA EA201290901A patent/EA201290901A1/ru unknown
-
2012
- 2012-09-10 IL IL221871A patent/IL221871A/en active IP Right Grant
- 2012-10-09 CO CO12177686A patent/CO6630103A2/es unknown
- 2012-10-09 ZA ZA2012/07574A patent/ZA201207574B/en unknown
-
2014
- 2014-04-24 US US14/260,876 patent/US9675654B2/en active Active
-
2016
- 2016-04-27 CY CY20161100356T patent/CY1117451T1/el unknown
- 2016-12-01 AU AU2016266059A patent/AU2016266059A1/en not_active Abandoned
-
2017
- 2017-06-12 US US15/620,435 patent/US20180042975A1/en not_active Abandoned
-
2018
- 2018-08-16 AU AU2018217273A patent/AU2018217273B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301340I2 (nl) | tisotumab vedotin | |
| NO2022039I1 (no) | Enfortumab vedotin | |
| PL2544682T3 (pl) | Fitokannabinoidy w leczeniu glejaka | |
| BR112012017441A2 (pt) | compostos e métodos | |
| PL2523678T3 (pl) | Antagoniści Wnt i sposoby leczenia | |
| IT1400425B1 (it) | Modified snrnas for use in therapy. | |
| SMT201600050B (it) | Mezzi e metodi per trattare il dlbcl | |
| DK2552261T3 (da) | Propfilter med proprum med aromakugle | |
| HRP20160737T1 (hr) | Anti-her3-protutijela i njihove uporabe | |
| DK2538984T3 (da) | Kompressionsforbinding | |
| LT2605789T (lt) | Modifikuoti relaksino polipeptidai ir jų panaudojimas | |
| DK3124610T3 (da) | Hbv-behandling | |
| DK2613884T3 (da) | Findelingsindretning | |
| IL232262A (en) | Therapeutic agents and uses thereof | |
| HRP20171579T8 (hr) | Antigljivična sredstva i njihova upotreba | |
| HRP20160922T1 (hr) | Oligopeptidni spojevi i njihove uporabe | |
| HRP20170936T1 (hr) | Alkilamido spojevi i njihova uporaba | |
| EP2872036A4 (en) | IN VIVO BIOSENSOR | |
| FR2963612B1 (fr) | Element en treillis et grue | |
| EP2613409A4 (en) | Connector | |
| EP2543712A4 (en) | IN COOLING MEDIUM | |
| IL229767A0 (en) | Glioblastoma inhibiting compounds and their use | |
| HRP20170225T1 (hr) | Fosfoplatini i njihova uporaba za liječenje karcinoma | |
| HRP20160929T1 (hr) | Terapijski režimi | |
| EP2415408A4 (en) | Treatment device |